Abstract
Irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) are highly prevalent gastrointestinal disorders. Traditional symptoms based therapies had somewhat limited success and efficacy in addressing the disorders. Recently, linaclotide emerged as novel peptide capable of improving abdominal symptoms in patients suffering from IBS-C and CIC. Guanylate cyclase C (GC-C) receptor a multi domain protein, found to be molecular target for linaclotide which acts by activating GC-C receptor on the apical surface of intestinal epithelial cells. Binding of linaclotide to GC-C receptor triggers the elevation of second messenger cGMP that elicits fluid secretion into intestinal cells which play a critical role in maintaining homeostasis through cystic fibrosis transmembrane conductance regulator (CFTR). Data from Phase and clinical trials demonstrated that linaclotide seems to produce a statistically significant increase in stool frequency, improved straining, decreased abdominal pain and discomfort.
Keywords: CIC, cGMP, guanylate cyclase C, homeostasis, IBS-C, Linaclotide.
Mini-Reviews in Medicinal Chemistry
Title:Linaclotide-a Novel Secretagogue in the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation
Volume: 13 Issue: 11
Author(s): Shivani Sharma, Tina Sharma, Richa Dhingra, Prince Tomar, Sukhminder Singh, Manav Malhotra and T. R. Bhardwaj
Affiliation:
Keywords: CIC, cGMP, guanylate cyclase C, homeostasis, IBS-C, Linaclotide.
Abstract: Irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) are highly prevalent gastrointestinal disorders. Traditional symptoms based therapies had somewhat limited success and efficacy in addressing the disorders. Recently, linaclotide emerged as novel peptide capable of improving abdominal symptoms in patients suffering from IBS-C and CIC. Guanylate cyclase C (GC-C) receptor a multi domain protein, found to be molecular target for linaclotide which acts by activating GC-C receptor on the apical surface of intestinal epithelial cells. Binding of linaclotide to GC-C receptor triggers the elevation of second messenger cGMP that elicits fluid secretion into intestinal cells which play a critical role in maintaining homeostasis through cystic fibrosis transmembrane conductance regulator (CFTR). Data from Phase and clinical trials demonstrated that linaclotide seems to produce a statistically significant increase in stool frequency, improved straining, decreased abdominal pain and discomfort.
Export Options
About this article
Cite this article as:
Sharma Shivani, Sharma Tina, Dhingra Richa, Tomar Prince, Singh Sukhminder, Malhotra Manav and Bhardwaj R. T., Linaclotide-a Novel Secretagogue in the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation, Mini-Reviews in Medicinal Chemistry 2013; 13 (11) . https://dx.doi.org/10.2174/1389557511313110011
DOI https://dx.doi.org/10.2174/1389557511313110011 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
COVID-19: Epidemiology, Pathology, Diagnosis, Treatment, and Impact
Current Pharmaceutical Design Prevalence of the Effects of Anxiety and Depression on People with Type 2 Diabetes Mellitus: An Analysis of Health Policy Studies in Improving the Quality of Life of Poor Families in the Urban Areas of West Lombok, Indonesia
Current Diabetes Reviews Therapeutic Agents for COVID-19: an Overview
Current Drug Therapy Asymmetric Synthesis of (S)-metoprolol via Sharpless Asymmetric Dihydroxylation Induced by A Recoverable Polymer Ligand QN-AQNOPEG- OMe
Letters in Organic Chemistry Chronic Migraineurs Form Carboxyhemefibrinogen and Iron-Bound Fibrinogen
CNS & Neurological Disorders - Drug Targets Potential Anticancer Effect of Carvacrol Codrugs on Human Glioblastoma Cells
Current Drug Delivery Optimization of Extraction and Pre-Concentration of Rizatriptan in Biological Samples Using Solvent Bar and Chemometrics Design
Current Pharmaceutical Analysis Alzheimer's Disease and Chinese Medicine as a Useful Alternative Intervention Tool: A Mini-Review
Current Alzheimer Research Natural Products as Promising Drug Candidates for the Treatment of Alzheimer’s Disease: Molecular Mechanism Aspect
Current Neuropharmacology Pharmacotherapy in Pedatric PTSD: A Developmentally-Focused Review of the Evidence
Current Psychopharmacology Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies
Current Clinical Pharmacology Recent Developments in Receptor-Selective Retinoids
Current Pharmaceutical Design Molecularly Imprinted Sol-Gel Materials for Medical Applications
Current Topics in Medicinal Chemistry Actigraphy for Assessing Light Effects on Sleep and Circadian Activity Rhythm in Alzheimer's Dementia: A Narrative Review
Current Alzheimer Research Bioactive Compounds in Some Culinary Aromatic Herbs and Their Effects on Human Health
Mini-Reviews in Medicinal Chemistry Update on Myositis Therapy: From Today’s Standards to Tomorrow’s Possibilities
Current Pharmaceutical Design Rivastigmine for Refractory REM Behavior Disorder in Mild Cognitive Impairment
Current Alzheimer Research Etiopathogenesis, Classical Immunotherapy and Innovative Nanotherapeutics for Inflammatory Neurological Disorders
Current Nanoscience Phosphodiesterase Type 5 Inhibitors for the Management of Erectile Dysfunction: Preference and Adherence to Treatment
Current Pharmaceutical Design <i>Ammoides verticillata</i> Essential Oil as Biocontrol Agent of Selected Fungi and Pest of Olive Tree
Recent Patents on Food, Nutrition & Agriculture